MedPath

Onvansertib

Generic Name
Onvansertib
Drug Type
Small Molecule
Chemical Formula
C24H27F3N8O3
CAS Number
1034616-18-6
Unique Ingredient Identifier
67RM91WDHQ

Overview

Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).

Background

Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
2024/12/17
NCT06736717
Phase 1
Recruiting
University of Kansas Medical Center
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
2024/05/03
NCT06398587
Phase 2
Withdrawn
OHSU Knight Cancer Institute
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
2023/10/30
NCT06106308
Phase 2
Active, not recruiting
Cardiff Oncology
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
2022/10/25
NCT05593328
Phase 2
Completed
Cardiff Oncology
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
2022/09/22
NCT05549661
Phase 1
Recruiting
Mayo Clinic
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
2022/07/11
NCT05450965
Phase 2
Recruiting
Taofeek Owonikoko
Onvansertib + Paclitaxel In TNBC
2022/05/20
NCT05383196
Phase 1
Active, not recruiting
Antonio Giordano, MD
Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma
2021/02/12
NCT04752696
Phase 2
Completed
Cardiff Oncology
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
2020/06/25
NCT04446793
N/A
NO_LONGER_AVAILABLE
Cardiff Oncology
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
2019/07/02
NCT04005690
Early Phase 1
Recruiting
OHSU Knight Cancer Institute

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy